<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03011892</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 18424-206</org_study_id>
    <nct_id>NCT03011892</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults With Atopic Dermatitis</brief_title>
  <official_title>A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream-Controlled Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the efficacy of each strength of INCB018424 cream
      once daily (QD) or twice daily (BID) in subjects with atopic dermatitis as compared with
      vehicle cream BID.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Actual">March 12, 2018</completion_date>
  <primary_completion_date type="Actual">January 10, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percentage change from baseline in Eczema Area and Severity Index (EASI) score at Week 4 in subjects treated with 1.5% INCB018424 BID compared with subjects treated with vehicle cream BID</measure>
    <time_frame>From baseline to Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean percentage change from baseline in EASI score at Week 4 in subjects treated with INCB018424 compared with subjects treated with vehicle cream BID</measure>
    <time_frame>From baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percentage change from baseline in EASI score at Week 4 in subjects treated with INCB018424 compared with subjects treated with triamcinolone 0.1% cream BID</measure>
    <time_frame>From baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving an Investigator's Global Assessment (IGA) score of 0 to 1 who have an improvement of ≥ 2 points from baseline at Week 4</measure>
    <time_frame>From baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the Itch Numerical Rating Scale (NRS) score at Week 4</measure>
    <time_frame>From baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessed by monitoring the frequency, duration, and severity of adverse events (AEs)</measure>
    <time_frame>From baseline to 1 month after end of treatment, up to 16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">307</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>INCB018424 cream 1.5% BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB018424 cream 1.5% applied BID for 8 weeks. At Week 8, subjects who meet criteria will be offered open-label treatment with INCB018424 1.5% cream BID for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB018424 cream 1.5% QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB018424 cream 1.5% applied QD for 8 weeks. At Week 8, subjects who meet criteria will be offered open-label treatment with INCB018424 1.5% cream BID for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB018424 cream 0.5% QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB018424 cream 0.5% applied QD for 8 weeks. At Week 8, subjects who meet criteria will be offered open-label treatment with INCB018424 1.5% cream BID for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB018424 cream 0.15% QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB018424 cream 0.15% applied QD for 8 weeks. At Week 8, subjects who meet criteria will be offered open-label treatment with INCB018424 1.5% cream BID for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone 0.1% cream BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vehicle cream applied BID for 4 weeks after triamcinolone 0.1% cream applied BID for initial 4 weeks.
At Week 8, subjects who meet criteria will be offered open-label treatment with INCB018424 1.5% cream BID for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle cream applied BID for 8 weeks. At Week 8, subjects who meet criteria will be offered open-label treatment with INCB018424 1.5% cream BID for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB018424 cream</intervention_name>
    <description>INCB018424 1.5% cream</description>
    <arm_group_label>INCB018424 cream 1.5% BID</arm_group_label>
    <arm_group_label>INCB018424 cream 1.5% QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB018424 cream</intervention_name>
    <description>INCB018424 0.5% cream</description>
    <arm_group_label>INCB018424 cream 0.5% QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB018424 cream</intervention_name>
    <description>INCB018424 0.15% cream.</description>
    <arm_group_label>INCB018424 cream 0.15% QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone 0.1% cream</intervention_name>
    <description>Triamcinolone 0.1% cream BID</description>
    <arm_group_label>Triamcinolone 0.1% cream BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle cream</intervention_name>
    <arm_group_label>Triamcinolone 0.1% cream BID</arm_group_label>
    <arm_group_label>Vehicle cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects diagnosed with atopic dermatitis as defined by the Hanifin and Rajka
             criteria.

          -  Subjects with a history of atopic dermatitis for at least 2 years.

          -  Subjects with an Investigator's Global Assessment score of 2 to 3 at screening and
             baseline.

          -  Subjects with body surface area of atopic dermatitis involvement, excluding the face
             and intertriginous areas, of 3% to 20% at screening and baseline.

          -  Subjects who agree to discontinue all agents used to treat atopic dermatitis from
             screening through the final follow-up visit.

        Exclusion Criteria:

          -  Subjects with evidence of active acute or chronic infections.

          -  Use of topical treatments for atopic dermatitis (other than bland emollients) within 2
             weeks of baseline.

          -  Systemic immunosuppressive or immunomodulating drugs (eg, oral or injectable
             corticosteroids, methotrexate, cyclosporine, mycophenolate mofetil, azathioprine)
             within 4 weeks or 5 half-lives of baseline (whichever is longer).

          -  Subjects with other dermatologic disease besides atopic dermatitis whose presence or
             treatments could complicate the assessment of disease (eg, psoriasis).

          -  Subjects with a history of other diseases besides dermatologic disorders (eg, other
             autoimmune diseases) taking treatments that could complicate assessments.

          -  Subjects with cytopenias at screening, defined as:

               -  Leukocytes &lt; 3.0 × 10^9/L.

               -  Neutrophils &lt; lower limit of normal.

               -  Hemoglobin &lt; 10 g/dL.

               -  Lymphocytes &lt; 0.8 × 10^9/L

               -  Platelets &lt; 100 × 10^9/L.

          -  Subjects with severely impaired liver function (Child-Pugh Class C) or end-stage renal
             disease on dialysis or at least 1 of the following:

               -  Serum creatinine &gt; 1.5 mg/dL.

               -  Alanine aminotransferase or aspartate aminotransferase ≥ 1.5 × upper limit of
                  normal.

          -  Subjects taking potent systemic cytochrome P450 3A4 inhibitors or fluconazole within 2
             weeks or 5 half-lives, whichever is longer, before the baseline visit (topical agents
             with limited systemic availability are permitted).

          -  Subjects who have previously received Janus kinase inhibitors, systemic or topical
             (eg, ruxolitinib, tofacitinib, baricitinib, filgotinib, lestaurtinib, pacritinib).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kuligowski, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB DERMATOLOGY, 2000 6th Avenue South</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BURKE PHARMACEUTICAL RESEARCH, 601 W. Commerce</name>
      <address>
        <city>Bryant</city>
        <state>Arkansas</state>
        <zip>72022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENCINO RESEARCH CENTER, 16133 Ventura Blvd</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DERMATOLOGY RESEARCH ASSOCIATES,8930 South Sepulveda Blvd</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DERMATOLOGY SPECIALISTS, INC, 3629 Vista Way</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INTEGRATED RESEARCH GROUP, INC, 4646 Brockton Avenue</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SAN LUIS DERMATOLOGY AND LASER CLINIC, 15 Santa Rosa Street</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEW ENGLAND RESEARCH ASSOCIATES LLC, 5520 Park Avenue</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DS RESEARCH, 2241 Green Valley Road</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>THE INDIANA CLINICAL TRIALS CENTER, 824 Edwards Drive</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DERMRESEARCH, 1169 Eastern Parkway 2310</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DS RESEARCH, 3810 Springhurst Blvd</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACTIVMED PRACTICES &amp; RESEARCH, INC, 138 Conant Street</name>
      <address>
        <city>Beverly</city>
        <state>Massachusetts</state>
        <zip>01915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TUFTS MEDICAL CENTER, 800 Washington Street</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HENRY FORD HOSPITAL, 3031 West Grand Blvd</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WASHINGTON UNIVERSITY - DERMATOLOGY, 4921 Parkview Place</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WASHINGTON UNIVERSITY - DERMATOLOGY, 969 Mason Road</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACTIVMED PRACTICES AND RESEARCH, INC, 110 Corporate Drive</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HASSMAN RESEARCH INSTITUTE, LLC, 175 Cross Keys Road</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DERMATOLOGY CONSULTING SERVICES, PLLC, 2444 North Main Street</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WAKE RESEARCH ASSOCIATES LLC, 3100 Duraleigh Road</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DERMATOLOGISTS OF GREATER COLUMBUS, 2359 East Main Street</name>
      <address>
        <city>Bexley</city>
        <state>Ohio</state>
        <zip>43209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RAPID MEDICAL RESEARCH, INC, 3619 Park East Drive</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CENTRAL SOONER RESEARCH, 900 North Porter</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PARISH DERMATOLOGY, INC, 1845 Walnut Street</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PEAK RESEARCH LLC, 2589 Washington Rd</name>
      <address>
        <city>Upper Saint Clair</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARLINGTON RESEARCH CENTER, INC, 711 East Lamar Blvd</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DERMRESEARCH INC., 8140 North Mopac Expressway</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J&amp;S STUDIES, INC, 1710 Crescent Pointe Pkwy</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CENTER FOR CLINICAL STUDIES (CCS), 1401 Binz</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUZANNE BRUCE AND ASSOCIATES, PA, 1900 St. James Place</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CLINICAL TRIALS OF TEXAS, INC, 7940 Floyd Curl Drive</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DERMATOLOGY CLINICAL RESEARCH CENTER OF SAN ANTONIO, 7810 Louis Pasteur</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CENTER FOR CLINICAL STUDIES, 451 North Texas Avenue</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHARLOTTESVILLE DERMATOLOGY, 600 Peter Jefferson Parkway</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INSTITUTE FOR SKIN ADVANCEMENT, 4935 40th Avenue Nw</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3A 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DR. CHIH-HO HONG MEDICAL INC., 15300 105 Avenue</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WISEMAN DERMATOLOGY RESEARCH INC, 6 - 1170 Taylor Avenue</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3M 3Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCA MEDICAL RESEARCH, 95 Bayly Street West</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>L1S 7K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SIMCODERM MEDICAL AND SURGICAL DERMATOLOGY CENTER, 5 Quarry Ridge Road</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LYNDERM RESEARCH INC, 25 Main Street Markham North</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DERMEDGE RESEARCH INC., 333 Lakeshore Road West</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5H 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NORTH BAY DERMATOLOGY CENTRE, 500 Cassells Street</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RESEARCH BY ICLS, 1344 Cornwall Road</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OFFICE OF DR. MICHAEL ROBERN, 1 Centrepointe Drive</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2G 6E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKIN CENTRE FOR DERMATOLOGY, 775 Monaghan Road</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>YORK DERMATOLOGY CENTER, 250 Harding Blvd West</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4C 9M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RESEARCH TORONTO, 208 Bloor Street West</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5Sz 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. PAPP CLINICAL RESEARCH, 135 Union Street East</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XLR8 MEDICAL RESEARCH, 2425 Tecumseh Road East</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WINDSOR CLINICAL RESEARCH INC, 2224 Walker Road</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CLINIQUE DERMATOLOGIQUE DE SAINT-JEROME, 555 Boul. Saint-antoine</name>
      <address>
        <city>Saint-jerome</city>
        <state>Quebec</state>
        <zip>J7Z 3B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2017</study_first_submitted>
  <study_first_submitted_qc>January 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2017</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic dermatitis</keyword>
  <keyword>eczema</keyword>
  <keyword>pruritus</keyword>
  <keyword>Janus kinase (JAK) inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

